SLS-004 Lowered Alpha-synuclein Levels in Mice
SLS-004, Seelos Therapeutics’ experimental epigenetic editing therapy for Parkinson’s disease, effectively reduced the production of alpha-synuclein — the protein that accumulates in toxic clumps in Parkinson’s — in the brains of healthy mice. Epigenetic modifications refer to the addition of chemical marks to DNA by a group of specialized…